| Quarterly Financials | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
Revenue  | 137 | 155 | 159 | 180 | 166 | 179 | 185 | 178 | 175 | 203 | 209 | 221 | 223 | 237 | 238 | 266 | 254 | 284 | 300 | 316 | 335 | 352 | 357 | 393 | 402 | 447 | 448 | 467 | 447 | 479 |
| Expenses | 103 | 116 | 125 | 139 | 125 | 132 | 135 | 131 | 125 | 143 | 146 | 159 | 157 | 173 | 179 | 202 | 202 | 210 | 214 | 224 | 234 | 253 | 249 | 282 | 281 | 305 | 310 | 321 | 298 | 329 |
| EBITDA | 35 | 39 | 35 | 41 | 41 | 47 | 50 | 47 | 50 | 60 | 63 | 63 | 66 | 64 | 59 | 64 | 51 | 74 | 86 | 92 | 101 | 99 | 108 | 112 | 121 | 142 | 138 | 146 | 149 | 150 |
| Operating Profit % | 23 % | 23 % | 20 % | 20 % | 23 % | 24 % | 25 % | 23 % | 27 % | 28 % | 28 % | 25 % | 26 % | 23 % | 22 % | 22 % | 19 % | 24 % | 25 % | 27 % | 27 % | 25 % | 27 % | 26 % | 27 % | 27 % | 27 % | 27 % | 26 % | 26 % |
| Depreciation | 9 | 9 | 10 | 10 | 10 | 10 | 11 | 10 | 11 | 11 | 13 | 13 | 13 | 14 | 14 | 14 | 14 | 14 | 14 | 15 | 16 | 16 | 16 | 16 | 20 | 21 | 22 | 21 | 23 | 25 |
| Interest | 4 | 7 | -1 | 2 | 3 | 2 | 5 | 8 | 3 | 3 | 5 | -2 | 3 | 0 | -1 | 2 | 1 | 0 | 5 | 2 | 3 | 2 | 4 | 3 | 3 | 3 | 3 | 2 | 3 | 3 |
| Profit Before Tax | 22 | 23 | 26 | 30 | 28 | 36 | 34 | 29 | 36 | 46 | 46 | 52 | 50 | 50 | 46 | 49 | 36 | 59 | 67 | 75 | 83 | 81 | 88 | 93 | 99 | 118 | 113 | 123 | 123 | 122 |
| Tax | 9 | 9 | 10 | 8 | 8 | 7 | 9 | 6 | 10 | 11 | 11 | 13 | 13 | 12 | 11 | 13 | 9 | 16 | 17 | 16 | 20 | 19 | 23 | 24 | 24 | 31 | 28 | 31 | 30 | 30 |
| Net Profit | 13 | 15 | 16 | 22 | 20 | 28 | 25 | 23 | 27 | 35 | 35 | 39 | 38 | 38 | 35 | 36 | 27 | 44 | 50 | 59 | 63 | 62 | 65 | 68 | 74 | 87 | 85 | 92 | 93 | 92 |
| EPS in ₹ | 1.50 | 1.65 | 1.82 | 2.44 | 2.24 | 3.22 | 2.83 | 2.57 | 3.03 | 3.97 | 4.00 | 4.26 | 3.92 | 3.99 | 3.60 | 3.77 | 2.81 | 4.53 | 5.21 | 6.13 | 6.54 | 6.48 | 6.78 | 7.12 | 7.71 | 9.01 | 8.48 | 8.92 | 9.19 | 9.06 |
Poly Medicure
Poly Medicure
2,034.30
+172.00
(9.24%)
Q1 Quarterly Results are out. Check out the updated financials15 hours ago
Show All
Key Fundamentals
Market Cap
20,612.69 Cr
EPS
34.13
PE Ratio
52.12
Dividend Yield
0.19 %
Industry
Healthcare 52 Week High
3,095.00
52 Week Low
1,821.20
PB Ratio
6.46
Debt to Equity
0.08
Sector
Medical Equipment Analyst Rating and Forecast
- By Refinitiv from5 analysts
Actual
Company News
View All News
Poly Medicure has lowered its revenue growth forecast for FY26 to 15-16%, down from its previous target of 20%. The company has revised its growth expectations downward by approximately 4-5 percentage points.
Poly Medicure reported Q2 consolidated net profit of 918.3 million rupees compared to 874.5 million rupees in the same period last year. Revenue increased to 4.44 billion rupees from 4.2 billion rupees year-over-year. EBITDA remained flat at 1.15 billion rupees, while EBITDA margin declined to 25.84% from 27.42% in the previous year.
Poly Medicure Acquires Full Ownership of Medistream SA, Gains Complete Control of Citieffe Group
4 days ago
4 days agoPoly Medicure has acquired full ownership of Medistream SA in Switzerland. Through this acquisition, the company now holds 100% ownership of Citieffe Group and its subsidiaries.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
2,034.30 | #1 20,612.69 | #5 52.12 | #1 1,759.00 | #5 22.62 | #1 339 | #5 5.03 | 42.18 | |
340.25 | 1,870.09 | 80.51 | 242.40 | 24.12 | 25 | -50.60 | 62.06 | |
269.70 | 1,434.97 | 52.14 | 408.40 | 32.64 | 30 | -55.00 | 11.27 | |
651.10 | 1,152.10 | 58.66 | 186.60 | - | 20 | - | 60.98 | |
577.80 | 960.40 | 62.98 | 249.37 | 40.00 | 17 | -20.59 | 40.47 | |
490.00 | 588.18 | #1 31.23 | 67.10 | 13.15 | 18 | 18.92 | 33.40 | |
271.95 | 517.79 | 33.23 | 136.30 | #1 107.77 | 16 | 50.00 | 57.17 | |
290.00 | 376.80 | 46.84 | 111.80 | -1.43 | 8 | 0.00 | 46.57 | |
273.20 | 287.23 | 40.22 | 89.85 | - | 7 | #1 892.83 | 50.39 | |
271.80 | 271.80 | 68.97 | 122.10 | - | 1 | 820.00 | 54.29 |
Growth Rate
Revenue Growth
22.62 %
Net Income Growth
31.09 %
Cash Flow Change
-9.64 %
ROE
-30.34 %
ROCE
-30.22 %
EBITDA Margin (Avg.)
6.13 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 364 | 387 | 457 | 565 | 654 | 767 | 1,224 | 1,377 | 1,577 | 1,859 | 3,193 |
| Fixed Assets | 166 | 182 | 207 | 265 | 306 | 363 | 426 | 488 | 635 | 867 | 1,084 |
| Current Assets | 160 | 171 | 205 | 255 | 302 | 318 | 704 | 783 | 807 | 842 | 1,917 |
| Capital Work in Progress | 10 | 14 | 20 | 18 | 19 | 25 | 21 | 43 | 78 | 76 | 101 |
| Investments | 0 | 0 | 3 | 17 | 8 | 25 | 354 | 346 | 126 | 167 | 1,077 |
| Other Assets | 189 | 191 | 227 | 264 | 321 | 354 | 422 | 499 | 738 | 749 | 930 |
| Total Liabilities | 364 | 387 | 457 | 565 | 654 | 767 | 1,224 | 1,377 | 1,577 | 1,859 | 3,193 |
| Current Liabilities | 113 | 109 | 114 | 123 | 154 | 197 | 171 | 227 | 293 | 351 | 370 |
| Non Current Liabilities | 55 | 50 | 72 | 104 | 119 | 135 | 87 | 63 | 42 | 37 | 57 |
| Total Equity | 196 | 229 | 272 | 338 | 381 | 435 | 966 | 1,088 | 1,242 | 1,470 | 2,766 |
| Reserve & Surplus | 174 | 207 | 227 | 294 | 337 | 391 | 918 | 1,040 | 1,194 | 1,422 | 2,715 |
| Share Capital | 22 | 22 | 44 | 44 | 44 | 44 | 48 | 48 | 48 | 48 | 51 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | -2 | 1 | 0 | 3 | 1 | 1 | 0 | 3 | -1 | 5 | -3 |
| Investing Activities | -59 | -31 | -56 | -88 | -101 | -110 | -436 | -85 | -179 | -241 | -1,194 |
| Operating Activities | 63 | 63 | 56 | 75 | 107 | 131 | 119 | 124 | 191 | 266 | 240 |
| Financing Activities | -6 | -31 | -0 | 16 | -5 | -21 | 317 | -35 | -13 | -20 | 951 |
Share Holding
| % Holding | Feb 2021 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Aug 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
| Promoter | 44.88 % | 44.88 % | 44.77 % | 44.77 % | 44.76 % | 44.66 % | 53.34 % | 53.33 % | 53.33 % | 53.31 % | 53.31 % | 53.16 % | 53.16 % | 53.15 % | 66.03 % | 62.56 % | 62.56 % | 62.44 % | 62.44 % | 62.44 % | 62.42 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 14.49 % | 0.00 % | 12.38 % | 9.91 % | 11.10 % | 11.87 % | 12.33 % | 11.46 % | 11.41 % | 9.77 % |
| DIIs | 1.83 % | 1.92 % | 2.68 % | 2.73 % | 2.86 % | 3.18 % | 3.10 % | 3.20 % | 3.38 % | 3.68 % | 4.25 % | 5.15 % | 5.28 % | 7.22 % | 9.35 % | 12.48 % | 12.33 % | 11.66 % | 11.96 % | 11.72 % | 13.54 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 16.24 % | 15.11 % | 14.24 % | 13.69 % | 13.24 % | 12.32 % | 11.93 % | 11.20 % | 11.18 % | 11.12 % | 11.10 % | 11.35 % | 11.38 % | 11.34 % | 11.37 % | 10.70 % | 10.14 % | 10.55 % | 11.08 % | 11.37 % | 11.25 % |
| Others | 37.06 % | 38.10 % | 38.30 % | 38.81 % | 39.14 % | 39.84 % | 31.63 % | 32.27 % | 32.11 % | 31.90 % | 31.34 % | 15.85 % | 30.17 % | 15.92 % | 3.36 % | 3.16 % | 3.10 % | 3.03 % | 3.07 % | 3.07 % | 3.02 % |
| No of Share Holders | 0 | 19,187 | 21,531 | 35,922 | 33,678 | 35,166 | 33,831 | 33,296 | 34,239 | 35,393 | 36,141 | 34,649 | 36,053 | 36,712 | 36,852 | 40,516 | 38,352 | 60,686 | 65,583 | 71,142 | 64,400 |
Dividend History
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 2.5 | 2 | 2 | 2 | 2.5 | 2.5 | 3 | 3 | 3.5 |
| Dividend Yield (%) | 0.00 | 1 | 0.91 | 0.86 | 0.24 | 0.26 | 0.27 | 0.19 | 0.13 | 0.19 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 28 Mar 2017 |  Bonus | 1:1 | 24 Mar 2017 | 0.00 | 0.00 |
| 17 Sept 2021 |  Dividend | ₹ 2.50 /share | 16 Sept 2021 | 1,133.15 | 955.00 |
| 19 Sept 2022 | Dividend | ₹ 2.50 /share | 16 Sept 2022 | 715.55 | 933.00 |
| 22 Sept 2023 | Dividend | ₹ 3.00 /share | 21 Sept 2023 | 977.25 | 1,413.65 |
| 20 Sept 2024 | Dividend | ₹ 3.00 /share | 19 Sept 2024 | 1,654.70 | 2,462.65 |
| 26 Sept 2024 |  Annual General Meeting | NA | 26 Sept 2024 | 2,498.45 | 2,318.00 |
| 28 Oct 2024 |  Quarterly Result Announcement | NA | 28 Oct 2024 | 2,450.95 | 2,514.10 |
| 03 Feb 2025 | Quarterly Result Announcement | NA | 03 Feb 2025 | 2,445.25 | 2,433.90 |
| 06 May 2025 | Quarterly Result Announcement | NA | 06 May 2025 | 2,587.85 | 2,584.60 |
| 08 Aug 2025 | Quarterly Result Announcement | NA | 08 Aug 2025 | 2,057.40 | 1,931.65 |
| 18 Sept 2025 | Dividend | ₹ 3.50 /share | 18 Sept 2025 | 2,584.60 | 1,996.60 |
| 25 Sept 2025 | Annual General Meeting | NA | 25 Sept 2025 | 2,067.00 | 1,981.35 |
| 08 Nov 2025 | Quarterly Result Announcement | NA | 08 Nov 2025 | 1,974.45 | 1,893.80 |
Announcements
Announcement under Regulation 30 (LODR)-Newspaper Publication18 hours ago
18 hours agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome18 hours ago
18 hours agoAnnouncement under Regulation 30 (LODR)-Investor Presentation2 days ago
2 days agoDeclaration Of Unaudited Financial Results For The Second Quarter And Half Year Ended For 30Th September 2025.3 days ago
3 days agoBoard Meeting Outcome for Outcome Of Board Meeting Held Hold Today I.E. 08Th November 2025 For Declaration Of Unaudited Financial Results(Standalone & Consolidated) For The Second Quarter And Half Year Ended 30Th September 2025 And For Other Businesses It3 days ago
3 days ago Announcement Under Regulation 30 (LODR)-Updates On Acquisition4 days ago
4 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation5 days ago
5 days agoBoard Meeting Intimation for Notice Of Board Meeting To Be Held On 08Th November 2025.10 days ago
10 days agoCompliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 13, 2025
Oct 13, 2025Transcript Of Investors/Analysts Conference Call Held On 25Th September 2025.Oct 01, 2025
Oct 01, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportSep 27, 2025
Sep 27, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeSep 25, 2025
Sep 25, 2025Closure of Trading WindowSep 25, 2025
Sep 25, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMSep 25, 2025
Sep 25, 2025Announcement under Regulation 30 (LODR)-Investor PresentationSep 25, 2025
Sep 25, 2025Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised)Sep 25, 2025
Sep 25, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 24, 2025
Sep 24, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseSep 24, 2025
Sep 24, 2025Announcement under Regulation 30 (LODR)-Investor PresentationSep 24, 2025
Sep 24, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSSep 24, 2025
Sep 24, 2025Outcome Of Board Meeting Held On Today I.E. 24Th September 2025 - Updates On Share Purchase Agreement For Acquisition Purpose Of "Citieffe Group"Sep 24, 2025
Sep 24, 2025Announcement under Regulation 30 (LODR)-Updates on AcquisitionSep 23, 2025
Sep 23, 2025Intimation For Cancellation Investor/Analyst Meet Scheduled To Be Held On Today I.E. 19.09.2025Sep 19, 2025
Sep 19, 2025Intimation Of Investor/Analyst Call Scheduled To Be Held On Friday 19Th September 2025Sep 17, 2025
Sep 17, 2025Revised Intimation For The Investors/Analyst One To One Virtual Call Scheduled To Be Held On Tuesday 16Th September 2025Sep 12, 2025
Sep 12, 2025Intimation Of Investor/Analyst One To One Virtual Meeting To Be Held On Tuesday 16Th September 2025Sep 12, 2025
Sep 12, 2025Intimation For The Analyst/Investor Call As On 11Th September 2025.Sep 09, 2025
Sep 09, 2025Tranascript Of Investor/Analyst Conference Call Held On 04Th September 2025.Sep 09, 2025
Sep 09, 2025Announcement under Regulation 30 (LODR)-Dividend UpdatesSep 05, 2025
Sep 05, 2025Book Closure For The Purpose Of Record Date For The Purpose Of DividendSep 05, 2025
Sep 05, 2025Record Date/Cut-Off Date For The Dividend PurposeSep 05, 2025
Sep 05, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeSep 04, 2025
Sep 04, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 04, 2025
Sep 04, 2025Intimation For Signing Of Share Purchase Agreement (SPA) Between Risor Holdings B.V. Amsterdam Netherlands A Wholly Owned Step-Down Subsidiary Of The Company With Wellinq Holdings B.V. Amsterdam Netherlands.Sep 04, 2025
Sep 04, 2025Intimation Of Dispatch Of Letter To Shareholders Whose E-Mail Addresses Are Not Registered With Company Or DepositoriesSep 03, 2025
Sep 03, 2025Business Responsibility and Sustainability Reporting (BRSR)Sep 03, 2025
Sep 03, 2025Reg. 34 (1) Annual Report.Sep 03, 2025
Sep 03, 202530Th Annual General Meeting To Be Held On Thursday September 25 2025.Sep 03, 2025
Sep 03, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 03, 2025
Sep 03, 2025Announcement under Regulation 30 (LODR)-Investor PresentationSep 03, 2025
Sep 03, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseSep 03, 2025
Sep 03, 2025Announcement under Regulation 30 (LODR)-AcquisitionSep 03, 2025
Sep 03, 2025Outcome Of Board Meeting_Acquisition(Incorporation Of A Wholly Owned Step Down Subsidiary "Risor Holdings B.V." In Amsterdam Netherlands And Updates On The Share Purchase Agreements (SPA)Sep 03, 2025
Sep 03, 2025Updates On Postponed And Rescheduled Investors/Analyst CallAug 28, 2025
Aug 28, 2025Investors/Analyst Call On Thursday 28Th August 2025Aug 26, 2025
Aug 26, 2025Announcement under Regulation 30 (LODR)-Updates on AcquisitionAug 20, 2025
Aug 20, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 14, 2025
Aug 14, 2025Statement Of Deviation Or Variation In The Use Of Proceeds Of Equity Shares Issued Through QIP For The Quarter Ended June 30 2025 As Per Regulation 32 Of The SEBI (Listing Obligations & Disclosures Requirements) Regulations 2015Aug 14, 2025
Aug 14, 2025Announcement under Regulation 30 (LODR)-Monitoring Agency ReportAug 14, 2025
Aug 14, 2025Disclosure Of Analyst/ Investor Virtual Calls/Physical Meet On Multiple DatesAug 13, 2025
Aug 13, 2025Mutual Fund Holdings
Invesco India ELSS Tax Saver Fund Direct-Growth 
WhiteOak Capital Flexi Cap Fund Direct - Growth 
Quant Multi Cap Fund Direct-Growth 
Nippon India Nifty Smallcap 250 Index Fund Direct - Growth 
Bank of India ELSS Tax Saver Direct-Growth 
SBI Nifty Smallcap 250 Index Fund Direct - Growth 
UTI Flexi Cap Fund Direct-Growth 
Tata Nifty MidSmall Healthcare Index Fund Direct - Growth 
ITI Pharma and Healthcare Fund Direct - Growth Technical Indicators
RSI(14)
Neutral 42.18
ATR(14)
Less Volatile 58.12
STOCH(9,6)
Neutral 34.83
STOCH RSI(14)
Oversold 9.10
MACD(12,26)
Bearish -2.06
ADX(14)
Weak Trend 12.74
UO(9)
Bearish 47.18
ROC(12)
Downtrend And Accelerating -3.74
WillR(14)
Oversold -84.29
About Poly Medicure
Poly Medicure Limited is an Indian medical device manufacturer founded in 1995. The company produces over 130 SKUs of medical devices across various product verticals including infusion therapy, oncology, anesthesia, respiratory care, urology, gastroenterology, blood management, surgery, and dialysis. Poly Medicure operates ten manufacturing facilities across India, China, Egypt, and Italy, with seven in India, one in China through a wholly-owned subsidiary, one in Egypt through an associate, and one in Italy through a step-down subsidiary. The company exports to over 110 countries through a network of more than 220 distributors. Poly Medicure's facilities are accredited with international quality certifications, including ISO 9001:2015 and EN ISO 13485:2016. The company has an R&D center in Faridabad, Haryana, approved by DSIR, focusing on developing new products and improving existing processes. Poly Medicure holds over 375 patents for its products in various therapeutic areas.
Website
Chairperson NameDevendra Raj Mehta
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
